Kymera Therapeutics, Inc. Depreciation in USD from Q3 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Kymera Therapeutics, Inc. quarterly/annual Depreciation history and growth rate from Q3 2019 to Q3 2025.
  • Kymera Therapeutics, Inc. Depreciation for the quarter ending September 30, 2025 was $2.1M, a 5% increase year-over-year.
  • Kymera Therapeutics, Inc. Depreciation for the twelve months ending September 30, 2025 was $7.4M, a 17.5% increase year-over-year.
  • Kymera Therapeutics, Inc. annual Depreciation for 2024 was $7.4M, a 106% increase from 2023.
  • Kymera Therapeutics, Inc. annual Depreciation for 2023 was $3.6M, a 20% increase from 2022.
  • Kymera Therapeutics, Inc. annual Depreciation for 2022 was $3M, a 25% increase from 2021.
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Growth (%)
Depreciation, Annual (USD)
Depreciation, YoY Annual Growth (%)

Kymera Therapeutics, Inc. Quarterly Depreciation (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $7.4M $2.1M +$100K +5% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-04
Q2 2025 $7.3M $1.7M -$200K -10.5% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-11
Q1 2025 $7.5M $1.6M +$100K +6.67% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-09
Q4 2024 $7.4M $2M +$1.1M +122% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-27
Q3 2024 $6.3M $2M +$1.1M +122% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-04
Q2 2024 $5.2M $1.9M +$1M +111% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-11
Q1 2024 $4.2M $1.5M +$600K +66.7% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-09
Q4 2023 $3.6M $900K +$100K +12.5% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-27
Q3 2023 $3.5M $900K +$100K +12.5% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-31
Q2 2023 $3.4M $900K +$200K +28.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $3.2M $900K +$200K +28.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 $3M $800K -$499K -38.4% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-27
Q3 2022 $3.5M $800K +$799K Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $2.7M $700K +$100K +16.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 $2.6M $700K +$200K +40% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $2.4M $1.3M +$799K +160% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-22
Q3 2021 $1.6M $700* -$499K Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $2.1M $600K +$200K +50% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $1.9M $500K +$100K +25% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-03
Q4 2020 $1.8M $500K Oct 1, 2020 Dec 31, 2020 10-K 2023-02-23
Q3 2020 $500K +$300K +150% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $400K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-06
Q1 2020 $400K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q3 2019 $200K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05

Kymera Therapeutics, Inc. Annual Depreciation (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $7.4M +$3.8M +106% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-27
2023 $3.6M +$600K +20% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-27
2022 $3M +$600K +25% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-27
2021 $2.4M +$600K +33.3% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-22
2020 $1.8M +$1M +125% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-23
2019 $800K Jan 1, 2019 Dec 31, 2019 10-K 2022-02-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.